156 related articles for article (PubMed ID: 38655138)
1. Comparison of chemotherapy and chidamide combined with chemotherapy in patients with untreated angioimmunoblastic T-cell lymphoma.
Gu S; Wang X; Zhou J; Du S; Niu T
Front Oncol; 2024; 14():1373127. PubMed ID: 38655138
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma.
Wang J; Su N; Fang Y; Ma S; Zhang Y; Cai J; Zou Q; Tian X; Xia Y; Liu P; Li Z; Huang H; Huang H; Cai Q
Front Immunol; 2022; 13():835103. PubMed ID: 35185926
[TBL] [Abstract][Full Text] [Related]
3. Comparison of chidamide-contained treatment modalities versus chemotherapy in the second-line treatment for relapsed or refractory peripheral T-cell lymphoma.
Wang J; Fang Y; Ma S; Su N; Zhang Y; Huang H; Li Z; Huang H; Tian X; Cai J; Xia Y; Liu P; Cai Q
Leuk Res; 2021 Dec; 111():106705. PubMed ID: 34534908
[TBL] [Abstract][Full Text] [Related]
4. Chidamide Maintenance Therapy Following Induction Therapy in Patients With Peripheral T-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Case Series From China.
Guo W; Wang X; Li J; Yin X; Zhao Y; Tang Y; Wang A; Bai O
Front Oncol; 2022; 12():875469. PubMed ID: 35747802
[TBL] [Abstract][Full Text] [Related]
5. Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase II trial.
Wang Y; Zhang M; Song W; Cai Q; Zhang L; Sun X; Zou L; Zhang H; Wang L; Xue H
Am J Hematol; 2022 May; 97(5):623-629. PubMed ID: 35170082
[TBL] [Abstract][Full Text] [Related]
6. Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas.
Wu M; Wang X; Xie Y; Liu W; Zhang C; Ping L; Ying Z; Deng L; Zheng W; Lin N; Tu M; Song Y; Zhu J
Int J Med Sci; 2018; 15(9):867-874. PubMed ID: 30008598
[No Abstract] [Full Text] [Related]
7. Successful Treatment of Chidamide and Cyclosporine for Refractory/Relapsed Angioimmunoblastic T Cell Lymphoma With Evans Syndrome: A Case Report With Long-Term Follow-Up.
Zhu F; Li Q; Pan H; Xiao Y; Liu T; Liu X; Li J; Wu G; Zhang L
Front Oncol; 2020; 10():1725. PubMed ID: 32984055
[TBL] [Abstract][Full Text] [Related]
8. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
[TBL] [Abstract][Full Text] [Related]
9. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Kyriakou C; Canals C; Goldstone A; Caballero D; Metzner B; Kobbe G; Kolb HJ; Kienast J; Reimer P; Finke J; Oberg G; Hunter A; Theorin N; Sureda A; Schmitz N;
J Clin Oncol; 2008 Jan; 26(2):218-24. PubMed ID: 18182664
[TBL] [Abstract][Full Text] [Related]
10. Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis.
Meeuwes FO; Brink M; van der Poel MWM; Kersten MJ; Wondergem M; Mutsaers PGNJ; Böhmer L; Woei-A-Jin S; Visser O; Oostvogels R; Jansen PM; Diepstra A; Snijders TJF; Plattel WJ; Huls GA; Vermaat JSP; Nijland M
Eur J Cancer; 2022 Nov; 176():100-109. PubMed ID: 36208568
[TBL] [Abstract][Full Text] [Related]
11. Long-time follow-up of patients with untreated peripheral T cell lymphoma following chidamide combined with cyclophosphamide, epirubicin, vindesine, prednisone, and etoposide therapy: a single-center propensity score-matching study.
Wei C; Zhao D; Zhang Y; Wang W; Zhou D; Zhang W
Clin Transl Oncol; 2023 Aug; 25(8):2514-2522. PubMed ID: 37020164
[TBL] [Abstract][Full Text] [Related]
12. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.
Park SI; Horwitz SM; Foss FM; Pinter-Brown LC; Carson KR; Rosen ST; Pro B; Hsi ED; Federico M; Gisselbrecht C; Schwartz M; Bellm LA; Acosta M; Advani RH; Feldman T; Lechowicz MJ; Smith SM; Lansigan F; Tulpule A; Craig MD; Greer JP; Kahl BS; Leach JW; Morganstein N; Casulo C; Shustov AR;
Cancer; 2019 May; 125(9):1507-1517. PubMed ID: 30694529
[TBL] [Abstract][Full Text] [Related]
13. Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation.
Kim SJ; Jo JC; Yoon DH; Yang DH; Yoon SE; Lee GW; Kong JH; Park Y; Kang KW; Lee HS; Oh SY; Shin HJ; Lee WS; Choi YS; Jeong SH; Kim MK; Kang HJ; Yi JH; Lim SN; Yhim HY; Do YR; Yun HJ; Eom HS; Lee MH; Suh C; Kim WS
Front Oncol; 2023; 13():1230629. PubMed ID: 37675232
[TBL] [Abstract][Full Text] [Related]
14. Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404).
Cho H; Yoon DH; Shin DY; Koh Y; Yoon SS; Kim SJ; Do YR; Lee GW; Kwak JY; Park Y; Kim MK; Kang HJ; Yi JH; Yoo KH; Lee WS; Park BB; Jo JC; Eom HS; Kim HJ; Jeong SH; Won YW; Sohn BS; Kwon JH; Suh C; Kim WS
Cancer Res Treat; 2023 Apr; 55(2):684-692. PubMed ID: 36596727
[TBL] [Abstract][Full Text] [Related]
15. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide)
Sun Y; Li L; Li X; Zhang L; Wang X; Fu X; Sun Z; Zhang X; Li Z; Wu J; Yu H; Chang Y; Yan J; Wu X; Zhou Z; Nan F; Tian L; Zhang M
Ther Adv Med Oncol; 2020; 12():1758835920923829. PubMed ID: 32550864
[TBL] [Abstract][Full Text] [Related]
17. Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma/leukemia.
Guan W; Jing Y; Dou L; Wang M; Xiao Y; Yu L
Leuk Lymphoma; 2020 Apr; 61(4):855-861. PubMed ID: 31755348
[TBL] [Abstract][Full Text] [Related]
18. The efficiency of autologous stem cell transplantation as the first-line treatment for nodal peripheral T-cell lymphoma: results of a systematic review and meta-analysis.
Zhai Y; Wang J; Jiang Y; Wu W; Lv Y; Xu H; Tian L; Sun H; Zhao Z; Li L
Expert Rev Hematol; 2022 Mar; 15(3):265-272. PubMed ID: 35152814
[TBL] [Abstract][Full Text] [Related]
19. The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study.
Feng X; Guo W; Wang Y; Li J; Zhao Y; Qu L; Yan X; Li J; Guo Q; Young KH; Bai O
Adv Ther; 2022 Jan; 39(1):532-543. PubMed ID: 34797505
[TBL] [Abstract][Full Text] [Related]
20. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]